NGS

Shaare Zedek Medical Center Uses SOPHiA GENETICS to Advance Research of Myeloid Disorders

Retrieved on: 
Friday, September 29, 2023
Database, Shaare Zedek Medical Center, European Hematology Association, Classification, NGS, Research, Disorder, Sophia, Sophia Genetics, Platform, GENETICS, EHA, Medicine, Artificial intelligence, Shaare Zedek, Pharmaceutical industry, Nursing, Medical device

BOSTON and ROLLE, Switzerland, Sept. 29, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Shaare Zedek, the largest multi-disciplinary medical center in Jerusalem, is now live on the SOPHiA DDM™ Platform. The Platform will enable Shaare Zedek to advance its insights the treatment of myeloid disorders and further develop the application of precision medicine.

Key Points: 
  • The Platform will enable Shaare Zedek to advance its insights the treatment of myeloid disorders and further develop the application of precision medicine.
  • Myeloid disorders affect millions of people worldwide, and while there are various types and classification of these disorders, collectively all myeloid disorders originate from hematopoietic disruptions in the myeloid lineage1.
  • Shaare Zedek Medical Center has been providing top-level medical research and care for the people of Jerusalem since 1902.
  • With the SOPHiA DDM™ Platform, Shaare Zedek Medical Center will retain complete ownership of its database, supporting the research team as it continues to increase its expertise.

Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS

Retrieved on: 
Thursday, September 28, 2023
Molecular biology, DNA, Therapy, Workflow, Telesis, NGS, Genomics, Messenger, Whole genome sequencing, SAN, Synthetic biology, Automation, Food delivery, Fine chemical

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® NGS Library Prep kit for Whole Genome Sequencing on the BioXp 3250 and BioXp 9600 systems.

Key Points: 
  • SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® NGS Library Prep kit for Whole Genome Sequencing on the BioXp 3250 and BioXp 9600 systems.
  • This NGS library prep kit enables on-demand and automated library preparation of up to 96 genomic DNA samples for use in whole genome sequencing applications.
  • Earlier this year we launched our first NGS Library Prep kit for Plasmid sequencing to streamline the workflow from synthesis to analysis.
  • For more information on BioXp® NGS Library Prep Kits please visit: https://telesisbio.com/products/bioxp-kits/ngs/

QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness

Retrieved on: 
Thursday, September 28, 2023
QIAGEN, QGEN, MD–PhD, Senior, Classification, NGS, Cancer, Intelligence, Literature, Publication, Patient, QCI, Genetic testing, Phenotype, Gene, NYSE, Genome, Software, Medical device, Medical imaging

The expansion complements the human-certified content curation of QCI Interpret and enables complete bibliographical coverage of the clinical exome.

Key Points: 
  • The expansion complements the human-certified content curation of QCI Interpret and enables complete bibliographical coverage of the clinical exome.
  • Additional AI-derived literature references for thousands of additional genes in the clinical genome to supplement QIAGEN-curated content.
  • “We help researchers to overcome this challenge by broadening the content of QCI Interpret, now covering the whole exome thanks to additional AI capabilities.
  • For example earlier this year, the Danish National Genome Center selected QCI Interpret for variant interpretation in oncology genome sequencing.

InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO

Retrieved on: 
Wednesday, September 27, 2023
Science, Other Science, Biotechnology, Research, General Health, Health, Technology, Other Technology, Interim, NGS, Medicines and Healthcare products Regulatory Agency, Liquid biopsy, Carolyn Bertozzi, Multimedia, Medication, Pharmaceuticals and Medical Devices Agency, RUO, Acquisition, Patient, IVD, Growth, Management, Medical imaging, Oncology, Archery

InterVenn Biosciences , the life sciences company pioneering glycoproteomic-based diagnostics, today announced that Joshua Stahl has been appointed as Chief Executive Officer to guide the company’s next phase of commercial growth.

Key Points: 
  • InterVenn Biosciences , the life sciences company pioneering glycoproteomic-based diagnostics, today announced that Joshua Stahl has been appointed as Chief Executive Officer to guide the company’s next phase of commercial growth.
  • View the full release here: https://www.businesswire.com/news/home/20230927452734/en/
    Joshua Stahl has been appointed as Chief Executive Officer to guide InterVenn's next phase of commercial growth.
  • (Photo: Business Wire)
    Mr. Stahl has a proven track record of building successful diagnostics companies.
  • Throughout his tenure, Mr. Stahl held leadership roles with increasing responsibility before becoming Chief Scientific Officer and Chief Operating Officer.

Integrated DNA Technologies Reveals Launch of xGen™ Products for Ultima Genomics®

Retrieved on: 
Wednesday, September 27, 2023
Research, General Health, Pharmaceutical, Oncology, Technology, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Other Technology, Health, Other Science, Learning, DNA, XGen Studios, Genomics, NGS, Integrated DNA Technologies, Ligation, Multimedia, RNA, Manager, Chemistry, IDT, Ultima, WGS, Small Business Saturday, Integration, PCR, Fine chemical, Antibiotics, Birth control, Paint

With a mission to accelerate the pace of genomics, Integrated DNA Technologies (IDT), a leading provider of differentiated next generation sequencing (NGS) solutions, announces the availability of xGen NGS products designed exclusively for the Ultima Genomics UG 100™ platform.

Key Points: 
  • With a mission to accelerate the pace of genomics, Integrated DNA Technologies (IDT), a leading provider of differentiated next generation sequencing (NGS) solutions, announces the availability of xGen NGS products designed exclusively for the Ultima Genomics UG 100™ platform.
  • The products are designed to minimize sequence errors from PCR or sequencing that might impact demultiplexing.
  • xGen HybCap Adapters for Ultima Genomics—full-length adapters for library construction prior to hybridization capture, using TA-ligation workflows for incorporating sample indexing during the ligation step.
  • xGen HybCap Lib Amp Primers for Ultima Genomics—premixed PCR primers used to increase yield for sequencing libraries post-hybridization capture.

Golden Helix Receives New NIH SBIR Grant

Retrieved on: 
Tuesday, September 26, 2023
Pharmacogenomics, NGS, Genetic testing, Disulfiram-like drug, Biomarker, PI, Research, Patient, NIH, Safety, Pharmaceutical industry

BOZEMAN, Mont., Sept. 26, 2023 /PRNewswire/ -- Golden Helix, Inc. announced that it was awarded the NIH SBIR Grant 1R43HG013456-01 "Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options."

Key Points: 
  • BOZEMAN, Mont., Sept. 26, 2023 /PRNewswire/ -- Golden Helix, Inc. announced that it was awarded the NIH SBIR Grant 1R43HG013456-01 "Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options."
  • Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice, dosage, efficacy, and safety for individual patients.
  • This grant allows Golden Helix to research pharmacogenetics analytics capabilities as an integrated component of NGS-based genetic testing.
  • The PI of this grant Dr. Scherer, President and CEO of Golden Helix, says, "Our long-term goal is to support healthcare providers to enhance clinical outcomes, reduce adverse drug reactions, and achieve cost-effective healthcare by integrating pharmacogenomics into routine clinical practice.

ePlus Team Joins Habitat for Humanity of Durham for Community Build

Retrieved on: 
Tuesday, September 26, 2023
PLUS, Volunteering, Humanity, NGS, Organization, Partnership, Housing, EPlus, Work, News, Management

HERNDON, Va., Sept. 26, 2023 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS – news ) today announced that a team of ePlus employee volunteers joined forces with Habitat for Humanity of Durham to assist in the building of affordable houses in the area.

Key Points: 
  • HERNDON, Va., Sept. 26, 2023 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS – news ) today announced that a team of ePlus employee volunteers joined forces with Habitat for Humanity of Durham to assist in the building of affordable houses in the area.
  • ePlus has partnered with Habitat for Humanity since 2018 on builds at various locations across the U.S., including Virginia, California and Texas.
  • This year's build in Durham, North Carolina, will span two dates in September and October, with the first focusing on one of Durham Habitat's North Plum Street sites, a high-density development east of downtown Durham.
  • "We are very thankful to ePlus for its continued partnership and commitment to our mission," said Tiana Joyner, CEO, Habitat for Humanity of Durham.

Mission Bio Announces Launch of Single-Cell Measurable Residual Disease (MRD) Assay Aimed to Advance Personalized Healthcare for Blood Cancer Patients

Retrieved on: 
Tuesday, September 26, 2023
Translation, DNA, Science Advances, Multiple myeloma, NGS, Bone marrow, Clinical trial, Erasmus MC, Biomarker, Erasmus, Doctor of Philosophy, Acute myeloid leukemia, B cell, MRD, AOC, AML, MD, Translational research, Patient, Tapestry lawn, SAN, European, Flow cytometry, Medicine, MSK, MM, Recurrence, Gene, Vaccine, Medical imaging

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 /PRNewswire/ -- Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay. The company designed the scMRD AML Multiomics Assay to bring unprecedented resolution to disease relapse and recurrence in acute myeloid leukemia (AML), demonstrating the potential of single-cell DNA and protein multiomics to identify therapeutic targets in recurrent AML.

Key Points: 
  • Tapestri could transform care with comprehensive MRD detection for potentially guiding targeted treatments in AML, multiple myeloma (MM), and other blood cancers."
  • "Relapse continues to be a major challenge in cancer care, especially in the treatment of patients with AML.
  • "Mission Bio's unique approach to characterizing MRD could dramatically change how we stratify patients in clinical trials and create personalized care strategies in the future."
  • The researchers found that the assay could detect clinically relevant variants missed by bulk next-generation sequencing with 0.01% limit of detection.

Genius Sports launches BetVision, a game-changing, immersive sports betting experience including NFL live game video

Retrieved on: 
Tuesday, September 26, 2023
Software, Online, Entertainment, Sports, Internet, General Sports, Apps, Applications, Technology, Football, General Entertainment, Audio, Video, Casino, Gaming, NGS, Sport, NFL, Genius Sports, Growth, NYSE

Genius Sports is launching BetVision with NFL live games in the U.S.

Key Points: 
  • Genius Sports is launching BetVision with NFL live games in the U.S.
    For the first time ever, BetVision will allow sportsbook customers to place wagers from within the live video player in the sportsbook app.
  • These low latency live game video streams feature integrated betting odds and betslips and will be enhanced by in-game betting alerts and on-screen offers during breaks in game action to increase relevance, drive engagement and retain customers.
  • In the initial launch, U.S. sports betting operators Caesars Sportsbook and Fanatics Sportsbook are the first to be live with the product.
  • BetVision alone offers precisely that, while giving sportsbooks a new way to drive engagement and accelerate the growth of in-game betting.”

Omixon Launches NanoTYPE MONO™ and MONOall™ RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION™ Platform

Retrieved on: 
Monday, September 25, 2023
Oxford Nanopore Technologies, HLA, Workflow, Product innovation, NGS, TM, Medicine, Research, MONO, SSOP, RUO, Laboratory, Genetic testing, Disease

This cutting-edge technology is set to help clinical laboratories in the field of genetic marker assessment, providing an unprecedented level of accuracy at a competitive pricing structure.

Key Points: 
  • This cutting-edge technology is set to help clinical laboratories in the field of genetic marker assessment, providing an unprecedented level of accuracy at a competitive pricing structure.
  • As a result, many laboratories have relied on molecular techniques such as SSOP or RT-PCR, with lower resolution.
  • NanoTYPE MONO enables labs of all sizes and budgets to enhance their genetic testing capabilities while seamlessly integrating with the compact and environmentally friendly MinION system.
  • To learn more about NanoTYPE MONO and its transformative capabilities for clinical laboratories, please visit www.omixon.com/products/nanotype-mono/